Молекулярные маркеры при мышечно - неинвазивном раке мочевого пузыря

Молекулярные маркеры при мышечно - неинвазивном раке мочевого пузыря

Автор: Джикия Е.Л., Кулинич Т.М., Захаренко М.В., Боженко В.К.

Журнал: Вестник Российского научного центра рентгенорадиологии Минздрава России @vestnik-rncrr

Рубрика: Обзоры

Статья в выпуске: 4 т.19, 2019 года.

Бесплатный доступ

Рак мочевого пузыря (РМП) - тяжёлое инвалидизирующее заболевание, для которого не разработано системы активного выявления. РМП требует тщательной дифференциальной диагностики, имеет большую склонность к рецидивированию и прогрессированию. Одной из основных клинических проблем при РМП является прогнозирование исхода заболевания, поиск прогностических факторов, который в основном ориентирован на молекулярные маркеры. Выявление молекулярных маркеров, которые могут перейти в диагностические или прогностические инструменты является приоритетной задачей.

Молекулярный маркер, рак мочевого пузыря, онкоген

Короткий адрес: https://sciup.org/149132119

IDR: 149132119

Список литературы Молекулярные маркеры при мышечно - неинвазивном раке мочевого пузыря

  • Боженко В.К., Каприн А.Д., Костин А.А. и др. Проточная цитометрия осадка мочи в диагностике рака мочевого пузыря. Вопросы онкологии. 2007. Т. 53. № 4. С. 468-472.
  • Боженко В.К., Каприн А.Д., Кулинич Т.М., Нестеров П.В. Проточная цитометрия осадка мочи в диагностике рака мочевого пузыря. Вопросы онкологии. 2009. Т. 55. № 3. С. 278-284.
  • Боженко В.К., Кулинич Т.М., Нестеров П.В. Результаты анализа клеточного цикла осадка мочи больных раком мочевого пузыря. Вестник Российского научного центра рентгенорадиологии Минздрава России. 2008. № 8. http://vestnik.rncrr.ru/vestnik/v8/papers/bozh_v8.htm.
  • Каприн Д., Боженко В.К., Кулинич Т.М.и др. Проточная цитофлуориметрия осадка мочи в диагностике рака мочевого пузыря. Вопросы онкологии. 2006. Т. 52. № 5. С. 579-581.
  • Понукалин А.Н., Маслякова Г.Н., Захарова Н.Б., Цмокалюк Е.Н. Панель молекулярнобиологических и иммуногистохимических онкомаркеров при раке мочевого пузыря. Бюллетень медицинских Интернет-конференций. 2017. Т. 7. Выпуск 2 (Февраль).
  • Ролевич А.И., Смаль М.П., Красный С. А., Гончарова Р.И. Роль мутационного статуса гена FGFR3в предсказании прогрессирования рака мочевого пузыря без мышечной инвазии. Онкоурология. 2015. Т. 3. № 11. С. 62-70.
  • Смальт П., Кужир Т., Ролевич А.И., Поляков С.Л. и др. Мутационный статус гена FGFR3 в проспективной когорте пациентов, страдающих раком мочевого пузыря. Доклады Национальной Академии наук Белоруси. 2013. Т. 57. № 1. С. 62-70.
  • Akhidova E.V., Volkova T.D., Koroev D.O., et al. Antibodies to synthetic peptides for the detection of survivin in tumor tissues. Bioorg Khim. 2010. V. 36. No. 2. P. 178-186.
  • Arafat W., Ashry M.S.E., Alrazek M.M.M., et al. The relation between survivin gene expression and urinary bladder cancer disease. Hos Pal Med Int Jnl. 2017. V. 1. No. 2. P. 26-33.
  • Billerey C., Chopin D., Aubriot-Lorton M.H., et al. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Am J Pathol. 2001. V. 158. No. 6. P. 1955-1959.
  • Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014. V. 507. No. 7492. P. 315-322.
  • DOI: 10.1038/nature12965
  • Cappellen D., De Oliveira C., Ricol D., et al. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Nat Genet. 1999. V. 23. No.1. P. 18-20.
  • Chang S.S., Boorjian S.A., Chou R., et al. Diagnosis and treatment of non-muscle invasive bladder cancer: AUA/SUO guideline. J Urol. 2016. V. 196. No. 4. P. 1021-1029.
  • DOI: 10.1016/j.juro.2016.06.049
  • Chen D., Xu J., Zhang Q. Detection of survivin expression in bladder cancer and renal cell carcinoma using specific monoclonal antibodies. Oncol Rep. 2018. V. 39. No. 6. P. 2817- 2828.
  • DOI: 10.3892/or.2018.6359
  • Du J., Wang S., Yang Q., et al. p53 status correlates with the risk of progression in stage T1 bladder cancer: a meta-analysis. World J Surg Oncol. 2016. V. 14. Article ID 137.
  • DOI: 10.1186/s12957-016-0890-9
  • Eissa S., Badr S., Elhamid S.A., et al. The Value of Combined Use of Survivin mRNA and Matrix Metalloproteinase 2 and 9 for Bladder Cancer Detection in Voided Urine. Dis Markers. 2013. V. 34. No. 1. P. 57-62.
  • DOI: 10.3233/DMA-2012-0923
  • Fristrup N., Ulhøi B.P., Birkenkamp-Demtröder K., et al. Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol. 2012. V. 180. No. 5. P. 1824-1834.
  • DOI: 10.1016/j.ajpath.2012.01.023
  • Fritsche H.M., Burger M., Svatek R.S., et al. Characteristics and outcomes of patients with clinical T1 grade 3 urothelial carcinoma treated with radical cystectomy: results from an international cohort. Eur Urol. 2010. V. 57. No. 2. P. 300-309.
  • DOI: 10.1016/j.eururo.2009.09.024
  • Giella J.G., Ring K., Olsson C.A., et al. The predictive value of flow cytometry and urinary cytology in follow-up of patients with transitional cell carcinoma of the bladder. J Urol. 1992. V. 148. No. 2. Pt 1. P. 293-296.
  • Guancial E.A., Werner L., Bellmunt J., et al. FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder. Cancer Med. 2014. V. 3. No. 4. P. 835-844.
  • DOI: 10.1002/cam4.262
  • Hedegaard J., Lamy P., Nordentoft I., et al. Comprehensive transcriptional analysis of early-stage urothelial carcinoma. Cancer Cell. 2016. V. 30. No. 1. P. 27-42.
  • Hernández S., López-Knowles E., Lloreta J., et al. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis. Clin Cancer Res. 2005. V. 11. No.15. P. 5444-5450.
  • Huang Y.J., Qi W.X., He A.N., et al. Prognostic value of tissue vascular endothelial growth factor expression in bladder cancer: a meta-analysis. Asian Pac J Cancer Prev. 2013. V. 14. No. 2. P. 645-649.
  • Jeon C., Kim M., Kwak C., et al. Prognostic role of survivin in bladder cancer: a systematic review and meta-analysis. PLoS One. 2013. V. 8. No. 10. e76719.
  • DOI: 10.1371/journal.pone.0076719
  • Karam J.A., Lotan Y., Karakiewicz P.I., et al. Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol. 2007. V.8. No. 2. P. 128-136.
  • DOI: 10.1016/S1470-2045(07)70002-5
  • Knowles M.A., Hurst C.D. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015. V. 15. P. 25-41.
  • Kopparapu P. K., Boorjian S. A., Robinson B. D., et al. Expression of VEGF and Its receptors VEGFR1/VEGFR2 is associated with invasiveness of bladder cancer. Anticancer Research. 2013. V. 33. No. 6. P. 2381-2390.
  • Liedberg F., Hagberg O., Holmang S., et al. Local recurrence and progression of nonmuscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol. 2015. V. 49. No. 4. P. 290-295.
  • Mbeutcha A., Mathieu R., Rouprêt M., et al. Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. Transl Androl Urol. 2016. V. 5. No. 5. P. 720-734.
  • DOI: 10.21037/tau.2016.09.07
  • Passoni N., Gayed B., Kapur P., et al. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscleinvasive high-grade bladder cancer. Urol Oncol. 2016. V. 34. No. 11. 485. e7-485.e14.
  • DOI: 10.1016/j.urolonc.2016.05.014
  • Puntoni M., Petrera M., Campora S., et al. Prognostic Significance of VEGF after Twenty-Year Follow-up in a Randomized Trial of Fenretinide in Non-Muscle-Invasive Bladder Cancer. Cancer Prevention Research. 2016. V. 9. No. 6. P. 437-444. :
  • DOI: 10.1158/1940-6207.CAPR-15-0345
  • Remy E., Rebouissou S., Chaouiya C., et al. A Modeling Approach to Explain Mutually Exclusive and Co-Occurring Genetic Alterations in Bladder Tumorigenesis. Cancer Res. 2015. V. 75. No. 19. P. 4042-4052.
  • Rink M., Chun F.K., Dahlem R., et al. Prognostic role and HER2 expression of circulating tumor cells in peripheral blood of patients prior to radical cystectomy: a prospective study. Eur Urol. 2012. V. 61. No. 4. P. 810-817.
  • DOI: 10.1016/j.eururo.2012.01.017
  • Rink M., Chun F.K., Minner S., et al. Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer. BJU Int. 2011. V. 107. No. 10. P. 1668-1675.
  • DOI: 10.1111/j.1464-410X.2010.09562.x
  • Sanguedolce F., Cormio A., Calò B., et al. Molecular markers predicting disease outcome in bladder cancer. Should we shift from the classical cell-cycle regulators to HER2 oncogene? Journal of Gerontology and Geriatrics. 2018. V. 66. P. 239-244.
  • Shariat S.F., Ashfaq R., Karakiewicz P.I., et al. Survivin expression is associated with bladder cancer presence, stage, progression, and mortality. cancer. 2007. V.109. No. 6. P. 1106-1113.
  • DOI: 10.1002/cncr.22521
  • Shariat S.F., Zlotta A.R., Ashfaq R., et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol. 2007. V. 20. No. 4. P. 445-459.
  • DOI: 10.1038/modpathol.3800757
  • Shariat S.F., Chade D.C., Karakiewicz P.I., et al. Combination of multiple molecular markers can improve prognostication in patients with locally advanced and lymph node positive bladder cancer. J Urol. 2010. V. 183. No. 1. P. 68-75.
  • DOI: 10.1016/j.juro.2009.08.115
  • Shariat S.F., Lotan Y., Saboorian H., et al. Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer. 2004. V. 100. No. 4. P. 751-757.
  • DOI: 10.1002/cncr.20039
  • Singh D., Chan J.M., Zoppoli P., et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science. 2012. V. 337. No. 6099. P. 1231-1235.
  • Soria F., Krabbe L.M., Todenhöfer T., et al. Molecular markers in bladder cancer. World Journal of Urology. 2019. V. 37. No. 1. P. 31-40.
  • Srivastava A.K., Singh P.K., Srivastava K., et al. Diagnostic role of survivin in urinary bladder cancer. Asian Pac J Cancer Prev. 2013. V. 14. No. 1. P. 81-85.
  • Stadler W.M., Lerner S.P., Groshen S., et al. Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011. V. 29. No. 25. P. 3443-3449.
  • DOI: 10.1200/jco.2010.34.4028
  • Tilki D., Burger M., Dalbagni G., et al. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Eur Urol. 2011. 60. No. 3. P. 484-492.
  • DOI: 10.1016/j.eururo.2011.05.053
  • Tomlinson D.C., Hurst C.D., Knowles M.A. Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. Oncogene. 2007. V. 26. No. 40. P. 5889-5899.
  • Tomlinson D.C., L'Hôte C.G., Kennedy W., et al. Alternative splicing of fibroblast growth factor receptor 3 produces a secreted isoform that inhibits fibroblast growth factor-induced proliferation and is repressed in urothelial carcinoma cell lines. Cancer Res. 2005. V. 65. No. 22. P. 10441-10449.
  • Van Kessel KEM., van der Keur K.A, Dyrskjøt L., et al. Molecular Markers Increase Precision of the European Association of Urology Non-Muscle-Invasive Bladder Cancer Progression Risk Groups. Clin Cancer Res. 2018. V. 24. No. 7. P. 1586-1593.
  • DOI: 10.1158/1078-0432.CCR-17-2719
  • Van Oers J.M., Adam C., Denzinger S., et al. Chromosome 9 deletions are more frequent than FGFR3 mutations in flat urothelial hyperplasias of the bladder. Int J Cancer. 2006. V. 119. No. 5. P. 1212-1215.
  • Van Rhijn B.W., van der Kwast T.H., Vis A.N., et al. FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma. Cancer Res. 2004. 64. No. 6. P. 1911-1914.
  • Van Rhijn B.W., van Tilborg A.A., Lurkin I., et al. Novel fibroblast growth factor receptor (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders. Eur J Hum Genet. 10. No. 12. P. 819-824.
  • Veltman J.A., Fridlyand J., Pejavar S., et al. Array-based comparative genomic hybridization for genome-wide screening of DNA copy number in bladder tumors. Cancer Res. 2003. V. 63. No. 11. P. 2872-2880.
  • Wesche J., Haglund K., Haugsten E.M. Fibroblast growth factors and their receptors in cancer. Biochem J. 2011. V. 437. No. 2. P. 199-213.
  • DOI: 10.1042/BJ20101603
  • Williams S.V., Hurst C.D., Knowles M.A. Oncogenic FGFR3 gene fusions in bladder cancer. Hum Mol Genet. 2013. V. 22. No. 4. P. 795-803.
  • Xylinas E., Kluth L.A., Lotan Y., et al. Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol. 2014. V. 32. No. 3. P. 230-242.
  • DOI: 10.1016/j.urolonc.2013.06.009
  • Xylinas E., Kent M., Kluth L. et al. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in nonmuscle- invasiveurothelial carcinoma of the bladder. Br J Cancer. 2013. V. 109. No. 6. P. 1460-1466.
  • Zhou X., Zhang G., Tian Y. p53 status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with bacillus Calmette-Guérin: a meta-analysis. PLoS One. 2015. V. 10. No. 3. e0119476.
  • DOI: 10.1371/journal.pone.0119476
Еще
Статья научная
SciUp 2024 © 2024 ©